Executive Summary Rare disease assessments rely on specialist clinical and patient expertise to inte...
As NICE and EU Joint Clinical Assessment (JCA) requirements increasingly need to be considered in pa...
Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.